NCT07386704Enrolling by invitationPhase 2
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
A Prospective, Single-arm Study of Nimotuzumab Combined With Radiotherapy and Chemotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitabine monotherapy). The primary endpoint of this study is the 1-year local control rate (LCR).
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- Dec 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07386704
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From Dec 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of abdominal radiotherapy.
- Those who have undergone major surgery within 30 days before screening.
Other illness
- Those with a history of other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ).
- Those allergic to the drugs or their components used in this protocol.
- Those with known HIV or syphilis infection, or currently in the active stage of hepatitis (hepatitis B or hepatitis C).
Lab values
- Those who have used EGFR monoclonal antibody or EGFR-TKI within 30 days before screening.
Other
- Pregnant or lactating women.
- Those judged by the investigator to have other reasons unsuitable for participating in this study.
Who the study is looking for
- Confirmed by histological or cytological examination as pancreatic adenocarcinoma;
- Confirmed by imaging as locally advanced or oligometastatic (number of metastatic lesions ≤ 3);
- Evaluated by the clinical doctor as inoperable or the patient refuses surgery;
- ECOG PS score 0-1;
- No radiotherapy has been performed on the upper abdomen before, and no any palliative chemotherapy or other systemic anti-tumor treatment has been received;
- According to the RECIST 1.1 evaluation criteria, there are measurable lesions;
- Sufficient organ and bone marrow functions
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiotherapy Oncology, Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.